PATENT CLAIM ANALYSIS

Application Number: 16094172
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "136100"]

Abstract:
The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.

Claim (Index 6):
The bispecific construct for the use according to any one of  claims 2  to  5 , wherein the treatment of the myeloid leukemia comprises two or more cycles of treatment which each comprises the maximal period of 14 days of construct administration followed by the period of at least 14 days without administration of the construct.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 97.0
- Lexical Diversity: 2.2449
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15934770', '12095951', '15604153', '14937494', '12101785']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6980336413503601
- 35 USC 102 Novelty (BERT): 0.5200760842031721
- Combined Prediction Score: 0.6802378856356412
- Mean Citation Score: 232.315448
- Max Citation Score: 239.4421
- Similarity Product: 138.6829874674797

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test